Royal UNIBREW A/S
7.9.2026 14:17:56 CEST | Globenewswire | Press release
Share buy-back program
Share buy-back program
COMPANY ANNOUNCEMENT NO 48/2026 - September 7, 2026
On August 17, 2026, Royal Unibrew announced a share buy-back program, cf. company announcement no. 44/2026.
The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of April 16, 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”).
The share buy-back program is expected to be realized in the period from August 18, 2026, to December 8, 2026. The total transaction value of the share buy-backs in the period will not exceed DKK 300m.
The following transactions have been made under the program:
| Number of Shares | Average purchase price DKK | Transaction value, DKK | |
| Accumulated, last announcement | 77,000 | 434.35 | 33,445,238 |
| August 31, 2026 | 10,000 | 430.25 | 4,302,471 |
| September 1, 2026 | 10,000 | 426.11 | 4,261,093 |
| September 2, 2026 | 12,000 | 419.82 | 5,037,896 |
| September 3, 2026 | 9,994 | 419.71 | 4,194,534 |
| September 4, 2026 | 9,000 | 419.38 | 3,774,417 |
| Total accumulated under the program | 127,994 | 429.83 | 55,015,649 |
With the transactions stated above Royal Unibrew owns a total of 1,910,582 shares, corresponding to 3.9% of the share capital. The total amount of shares in the company is 49,300,000, including treasury shares.
For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04
Encl.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom